PDF(Pubmed)
Abstract：
Introduction Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can upregulate the immune system and may contribute to glomerular disease (GD). Here, we describe a spectrum of GD that manifested following vaccination against SARS-CoV-2 (COVID-19 vaccinations). Material and methods This was a descriptive study of 10 cases enrolled between January 2021 and January 2023. Patients with biopsy-proven GD that manifested following COVID-19 vaccinations were included. Results We found 10 cases of biopsy-proven GD following the COVID-19 vaccination. This included five cases of minimal change disease (MCD), three cases of focal segmental glomerulosclerosis (FSGS), one case of C3 glomerulonephritis (C3GN), and one case of IgA nephropathy (IgAN). The pre-existing disease was found in the last two patients (IgAN and C3GN) who got unmasked following vaccination. We did not observe any relation between vaccine type (Covisheld; six cases vs. Covaxin; four cases) and GD. In most cases (8/10 cases, 80.0%), GD developed after a repeat dose (second or booster dose). The onset time following vaccination was typically less than a week, and even less following a repeat dose. Conclusion Post-vaccination GD can be either de novo or a flare-up of a pre-existing one. The onset time following vaccination was typically less than a week for both Covishield and Covaxin.
摘要：
简介针对严重急性呼吸道综合症冠状病毒2（SARS-CoV-2）的疫苗接种可以上调免疫系统，并可能导致肾小球疾病（GD）。这里,我们描述了在接种SARS-CoV-2（COVID-19疫苗）后表现出的一系列GD。材料和方法这是一项对2021年1月至2023年1月期间登记的10例病例的描述性研究。包括在COVID-19疫苗接种后出现活检证实的GD的患者。结果我们发现10例COVID-19疫苗接种后经活检证实的GD。其中包括5例微小病变（MCD），三例局灶节段肾小球硬化（FSGS），C3肾小球肾炎（C3GN）1例，IgA肾病(IgAN)1例。在接种疫苗后未被掩盖的最后两名患者（IgAN和C3GN）中发现了预先存在的疾病。我们没有观察到疫苗类型之间的任何关系(Covisheld；6例与Covaxin；4例）和GD。在大多数情况下（8/10例，80.0%），重复剂量（第二或加强剂量）后出现GD。接种疫苗后的起效时间通常不到一周，甚至更少的重复剂量。结论疫苗接种后GD可以是从头的，也可以是预先存在的GD的爆发。Covishield和Covaxin疫苗接种后的起效时间通常不到一周。
